Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Just when the basher arrives, AGN is HALTED

<< Previous

Bullboard Posts

Next >>

Comment by grosdavidon May 05, 2020 11:43am

99 Views

Post# 30987964

RE:RE:Just when the basher arrives, AGN is HALTED

Well said! Agree 100%. That's why I'm here, BIO/PHARMA as i posted last week can reach billion dollar cap without any revenue, that's how they work.

PHARMAS and BIO are EVALUATED ON POTENTIAL, SCIENCE and PATENTS (intellectual properties). That's all.

You can't compare test-kit company to a bio-pharma, they can patent so little and the market is open to competition. Pharma is different.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle